The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): Study protocol for a randomized controlled trial

Trials

Volumn 15, Issue 1, 2014, Pages

  Winther, Kristian H ^a   Watt, Torquil ^b   Bjørner, Jakob B ^b,c   Cramon, Per ^b   Feldt Rasmussen, Ulla ^b   Gluud, Christian ^d   Gram, Jeppe ^e   Groenvold, Mogens ^b,f   Hegedüs, Laszlo ^a   Knudsen, Nils ^f   Rasmussen, Åse K ^b   Bonnema, Steen J ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT   (Denmark)

^d Rigshospitalet   (Denmark)

^e ESBJERG HOSPITAL   (Denmark)

^f BISPEBJERG HOSPITAL   (Denmark)

Author keywords

chronic autoimmune thyroiditis; hypothyroidism; quality of life; selenium supplementation; ThyPRO

Indexed keywords

LEVOTHYROXINE; LIOTHYRONINE; PLACEBO; SELENIUM; SELENOPRECISE; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; FOLLOW UP; HASHIMOTO DISEASE; HUMAN; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT COMPLIANCE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELENIUM BLOOD LEVEL; SUPPLEMENTATION; THYROID PATIENT REPORTED OUTCOME QUESTIONNAIRE; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT DURATION;

AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DENMARK; DIETARY SUPPLEMENTS; FEMALE; HUMANS; IODIDE PEROXIDASE; IRON-BINDING PROTEINS; MALE; QUALITY OF LIFE; QUESTIONNAIRES; RESEARCH DESIGN; SELENIUM; THYROID GLAND; THYROID HORMONES; THYROIDITIS, AUTOIMMUNE; TIME FACTORS; TREATMENT OUTCOME; YEAST, DRIED;

EID: 84899472531     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-115     Document Type: Article

References (52)

1. Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med 1996, 335:99-107. 10.1056/NEJM199607113350206, 8649497.
2. Brix TH, Kyvik KO, Hegedus L. A population-based study of chronic autoimmune hypothyroidism in Danish twins. J Clin Endocrinol Metab 2000, 85(2):536-539.
3. Brix TH, Hegedüs L. Genetic predisposition versus environmental factors in autoimmune thyroid disease. The Thyroid and Environment 2000, 105-119. New York: Schattauer, Peter F, Wiersinga WM, Hostalek U.
4. Prummel MF, Strieder T, Wiersinga WM. The environment and autoimmune thyroid diseases. Eur J Endocrinol 2004, 150(5):605-618. 10.1530/eje.0.1500605, 15132715.
5. Pedersen IB, Laurberg P, Knudsen N, Jørgensen T, Perrild H, Ovesen L, Rasmussen LB. An increased incidence of overt hypothyroidism after iodine fortification of salt in Denmark: a prospective population study. J Clin Endocrinol Metab 2007, 92:3122-3127. 10.1210/jc.2007-0732, 17504896.
6. Carle A, Laurberg P, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Rasmussen LB, Jørgensen T. Epidemiology of subtypes of hypothyroidism in Denmark. Eur J Endocrinol 2006, 154:21-28. 10.1530/eje.1.02068, 16381987.
7. Tunbridge WM, Vanderpump MP. Population screening for autoimmune thyroid disease. Endocrinol Metab Clin North Am 2000, 29:239-253. 10.1016/S0889-8529(05)70129-8, 10874527.
8. Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP. ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J 2012, 2012(1):55-71.
9. Weetman AP. Cause of hypothyroidism: chronic autoimmune thyroiditis. Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text 2013, 525-535. Philadelphia, PA USA: Lippincott Williams & Wilkins, Braverman LE, Cooper DS, 10.
10. Watt T, Groenvold M, Rasmussen AK, Bonnema SJ, Hegedüs L, Bjorner JB, Feldt-Rasmussen U. Quality of life in patients with benign thyroid disorders: a review. Eur J Endocrinol 2006, 154:501-510. 10.1530/eje.1.02124, 16556711.
11. Watt T, Hegedus L, Rasmussen AK, Groenvold M, Bonnema SJ, Bjorner JB, Feldt-Rasmussen U. Which domains of thyroid-related quality of life are most relevant? Patients and clinicians provide complementary perspectives. Thyroid 2007, 17:647-654. 10.1089/thy.2007.0069, 17696835.
12. Watt T, Feldt-Rasmussen U, Rasmussen AK, Hegedüs L, Bonnema SJ, Gronvold M, Bjorner JB. Measurement of health-related quality of life in thyroid patients. Ugeskr Laeger 2008, 170:850-852.
13. Watt T, Rasmussen AK, Groenvold M, Bjorner JB, Watt SH, Bonnema SJ, Hegedüs L, Feldt-Rasmussen U. Improving a newly developed patient-reported outcome for thyroid patients, using cognitive interviewing. Qual Life Res 2008, 17:1009-1017. 10.1007/s11136-008-9364-z, 18584308.
14. Watt T, Bjorner JB, Groenvold M, Rasmussen AK, Bonnema SJ, Hegedüs L, Feldt-Rasmussen U. Establishing construct validity for the thyroid-related patient reported outcome measure (ThyPRO): an initial examination. Qual Life Res 2009, 18:483-496. 10.1007/s11136-009-9460-8, 19288224.
15. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf) 2002, 57:577-585. 10.1046/j.1365-2265.2002.01654.x, 12390330.
16. Panicker V, Evans J, Bjoro T, Asvold BO, Dayan CM, Bjerkeset O. A paradoxical difference in relationship between anxiety, depression and thyroid function in subjects on and not on T4: findings from the HUNT study. Clin Endocrinol (Oxf) 2009, 71:574-580. 10.1111/j.1365-2265.2008.03521.x, 19751298.
17. Thvilum M, Brandt F, Brix TH, Hegedus L. A review of the evidence for and against increased mortality in hypothyroidism. Nat Rev Endocrinol 2012, 8(7):417-424. 10.1038/nrendo.2012.29, 22392154.
18. Thvilum M, Brandt F, Almind D, Christensen K, Hegedus L, Brix TH. Excess mortality in patients diagnosed with hypothyroidism: a nationwide cohort study of singletons and twins. J Clin Endocrinol Metab 2013, 98(3):1069-1075. 10.1210/jc.2012-3375, 3590474, 23365121.
19. Thvilum M, Brandt F, Almind D, Christensen K, Brix TH, Hegedus L. Type and extent of somatic morbidity before and after the diagnosis of hypothyroidism. A nationwide register study. PloS One 2013, 8(9):e75789. 10.1371/journal.pone.0075789, 3774647, 24066186.
20. Thvilum M, Brandt F, Almind D, Christensen K, Brix TH, Hegedüs L. Increased psychiatric morbidity before and after the diagnosis of hypothyroidism: a nationwide register study. Thyroid 2014, doi:10.1089/thy.2013.0555.
21. Watt T, Hegedüs L, Bjorner JB, Groenvold M, Bonnema SJ, Rasmussen AK, Feldt-Rasmussen U. Is thyroid autoimmunity per se a determinant of quality of life in patients with autoimmune hypothyroidism?. Eur Thyroid J 2012, 1:186-192.
22. Rayman MP. Selenium and human health. Lancet 2012, 379:1256-1268. 10.1016/S0140-6736(11)61452-9, 22381456.
23. Rasmussen LB, Mejborn H, Andersen NL, Dragsted LO, Krogholm KS, Larsen EH. Selen og Sundhed 2006, Danmarks Fødevareforskning: Copenhagen.
24. Rasmussen LB, Schomburg L, Kohrle J, Pedersen IB, Hollenbach B, Hog A, Ovesen L, Perrild H, Laurberg P. Selenium status, thyroid volume, and multiple nodule formation in an area with mild iodine deficiency. Eur J Endocrinol 2011, 164:585-590. 10.1530/EJE-10-1026, 21242171.
25. Schomburg L, Kohrle J. On the importance of selenium and iodine metabolism for thyroid hormone biosynthesis and human health. Mol Nutr Food Res 2008, 52:1235-1246. 10.1002/mnfr.200700465, 18686295.
26. Combs GF, Midthune DN, Patterson KY, Canfield WK, Hill AD, Levander OA, Taylor PR, Moler JE, Patterson BH. Effects of selenomethionine supplementation on selenium status and thyroid hormone concentrations in healthy adults. Am J Clin Nutr 1808-1814, 2009:89.
27. Rayman MP, Thompson AJ, Bekaert B, Catterick J, Galassini R, Hall E, Warren-Perry M, Beckett GJ. Randomized controlled trial of the effect of selenium supplementation on thyroid function in the elderly in the United Kingdom. Am J Clin Nutr 2008, 87:370-378.
28. Gartner R, Gasnier BC, Dietrich JW, Krebs B, Angstwurm MW. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab 2002, 87:1687-1691. 10.1210/jcem.87.4.8421, 11932302.
29. Duntas LH, Mantzou E, Koutras DA. Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur J Endocrinol 2003, 148:389-393. 10.1530/eje.0.1480389, 12656658.
30. Gartner R, Gasnier BC. Selenium in the treatment of autoimmune thyroiditis. Biofactors 2003, 19:165-170. 10.1002/biof.5520190309, 14757967.
31. Turker O, Kumanlioglu K, Karapolat I, Dogan I. Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. J Endocrinol 2006, 190:151-156. 10.1677/joe.1.06661, 16837619.
32. Mazokopakis EE, Papadakis JA, Papadomanolaki MG, Batistakis AG, Giannakopoulos TG, Protopapadakis EE, Ganotakis ES. Effects of 12 months treatment with L-selenomethionine on serum anti-TPO levels in patients with Hashimoto's thyroiditis. Thyroid 2007, 17:609-612. 10.1089/thy.2007.0040, 17696828.
33. Karanikas G, Schuetz M, Kontur S, Duan H, Kommata S, Schoen R, Antoni A, Kletter K, Dudczak R, Willheim M. No immunological benefit of selenium in consecutive patients with autoimmune thyroiditis. Thyroid 2008, 18:7-12. 10.1089/thy.2007.0127, 18302514.
34. Balazs C. The effect of selenium therapy on autoimmune thyroiditis. Orv Hetil 2008, 149:1227-1232. 10.1556/OH.2008.28408, 18565817.
35. Kvicala J, Hrda P, Zamrazil V, Nemecek J, Hill M, Jiranek V. Effect of selenium supplementation on thyroid antibodies. J Radioanal Nucl Chem 2009, 280(2):275-279.
36. Nacamulli D, Mian C, Petricca D, Lazzarotto F, Barollo S, Pozza D, Masiero S, Faggian D, Plebani M, Girelli ME, Mantero F, Betterle C. Influence of physiological dietary selenium supplementation on the natural course of autoimmune thyroiditis. Clin Endocrinol (Oxf) 2010, 73:535-539.
37. Krysiak R, Okopien B. The effect of levothyroxine and selenomethionine on lymphocyte and monocyte cytokine release in women with Hashimoto's thyroiditis. J Clin Endocrinol Metab 2011, 96(7):2206-2215. 10.1210/jc.2010-2986, 21508145.
38. Anastasilakis AD, Toulis KA, Nisianakis P, Goulis DG, Kampas L, Valeri RM, Oikonomou D, Tzellos TG, Delaroudis S. Selenomethionine treatment in patients with autoimmune thyroiditis: a prospective, quasi-randomised trial. Int J Clin Pract 2012, 66:378-383. 10.1111/j.1742-1241.2011.02879.x, 22356267.
39. Zhu L, Bai X, Teng WP, Shan ZY, Wang WW, Fan CL, Wang H, Zhang HM. Effects of selenium supplementation on antibodies of autoimmune thyroiditis. Zhonghua Yi Xue Za Zhi 2012, 92:2256-2260.
40. Eskes SA, Endert E, Fliers E, Birnie E, Hollenbach B, Schomburg L, Kohrle J, Wiersinga WM. Selenite supplementation in euthyroid subjects with thyroid peroxidase antibodies. Clin Endocrinol (Oxf). 2014, 80:444-451. 10.1111/cen.12284, 23844613.
41. van Zuuren EJ, Albusta Amira Y, Fedorowicz Z, Carter B, Pijl H. Selenium supplementation for Hashimoto's thyroiditis. Cochrane Database Syst Rev 2013, 6:CD010223.
42. Vrca VB, Skreb F, Cepelak I, Romic Z, Mayer L. Supplementation with antioxidants in the treatment of Graves' disease; the effect on glutathione peroxidase activity and concentration of selenium. Clin Chim Acta 2004, 341(1-2):55-63.
43. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W. Selenium and the course of mild Graves' orbitopathy. N Engl J Med 1920-1931, 2011:364.
44. Watt T, Cramon P, Bjorner JB, Bonnema SJ, Feldt-Rasmussen U, Gluud C, Gram J, Hansen JL, Hegedüs L, Knudsen N, Bach-Mortensen P, Nolsoe R, Nygaard B, Pociot F, Skoog M, Winkel P, Rasmussen AK. Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial. Trials 2013, 14:119. 10.1186/1745-6215-14-119, 3748826, 23782950.
45. Cramon P, Rasmussen AK, Bonnema SJ, Bjorner JB, Feldt-Rasmussen U, Groenvold M, Hegedüs L, Watt T. Development and implementation of PROgmatic: a clinical trial management system for pragmatic multi-center trials, optimized for electronic data capture and patient-reported outcomes (PROs). Clin Trials 2014, doi:10.1177/1740774513517778.
46. Scientific Committee on Food Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level for Selenium. 1 2000, Brussels: European Commission, Scientific Committee on Food, Scientific Committee on Food.
47. Rayman MP. The use of high-selenium yeast to raise selenium status: how does it measure up?. Br J Nutr 2004, 92:557-573. 10.1079/BJN20041251, 15522125.
48. Rayman MP, Stranges S, Griffin BA, Pastor-Barriuso R, Guallar E. Effect of supplementation with high-selenium yeast on plasma lipids: a randomized trial. Ann Intern Med 2011, 154:656-665. 10.7326/0003-4819-154-10-201105170-00005, 21576533.
49. Winther K, Bonnema SJ, Hegedüs L, Rasmussen AK, Feldt-Rasmussen U, Bjorner JB, Groenvold M, Watt T. Development of a composite thyroid-specific quality of life scale for a randomized clinical trial among hypothyroid patients with chronic autoimmune thyroiditis, based on the ThyPRO questionnaire [abstract]. Qual Life Res 2013, 22(suppl.1):137. 3548091, 22331513.
50. International Conference on Harmonisation Guideline for Good Clinical Practice E6 (R1) 1996, Geneva, International Conference on Harmonisation.
51. Liu H, Wu T. Sample size calculation and power analysis of time-averaged difference. J Modern Appl Stat Meth 2005, 4:434-445.
52. Ware JH, Hamel MB. Pragmatic trials-guides to better patient care?. N Engl J Med 2011, 364:1685-1687. 10.1056/NEJMp1103502, 21542739.